US-Dutch biotech developing molecular-glue cancer therapeutics.
Founders
Christian Ottmann(Germany · ♂)— A leading academic in 14-3-3 protein biology, he co-founded Ambagon as CTO to turn his molecular-glue research into drugs that stabilize protein interactions on hard-to-drug cancer targets.
Michelle Arkin(United States · ♀)— A UCSF expert in drugging protein-protein interactions, she co-founded Ambagon to advance molecular glues targeting disordered proteins.
Luc Brunsveld(Netherlands · ♂)— A chemical-biology professor at TU Eindhoven, he co-founded Ambagon to commercialize 14-3-3 molecular-glue science for difficult oncology targets.
Members see the full profile
Create a free EquityFlow account to see Ambagon Therapeutics's 1 funding round, 5 investors, 12 similar companies.